Technical analysis of Eledon Pharmaceuticals, Inc. (ELDN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells.
Price Performance
| 1 month | -26.24% |
| 3 months | -31.89% |
| Year-to-date | +76.82% |
| 1 year | +9.88% |
| 3 years | +134.21% |
| 5 years | -61.86% |
52-Week Range
| 52-week High | $4.60 |
| 52-week Low | $1.35 |
| Avg Volume (90d) | 1.2M |
Technical Indicators
| SMA 50 | $3.46 |
| SMA 200 | $2.97 |
| Beta | 0.84 |
| 30-day Volatility (annualised) | 39.7% |
| Price vs SMA 50 | -22.7% |
| Price vs SMA 200 | -10.1% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $4.32 | |
| 2025-11 | $1.63 | -62.3% |
| 2025-12 | $1.51 | -7.4% |
| 2026-01 | $2.20 | +45.7% |
| 2026-02 | $2.62 | +19.1% |
| 2026-03 | $3.08 | +17.6% |
| 2026-04 | $3.64 | +18.2% |
| 2026-05 | $3.81 | +4.7% |
| 2026-06 | $3.94 | +3.4% |
| 2026-07 | $3.38 | -14.2% |
| 2026-08 | $2.98 | -11.8% |
| 2026-09 | $2.67 | -10.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | $-0.02 | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
Price
| Price | $2.67 |
| Market Cap | $206M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 4.21 |
| EV / EBITDA | -2.80 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 7.90 |